Skip to main content
. 2022 Mar 22;9:854230. doi: 10.3389/fcvm.2022.854230

TABLE 2.

Biochemical and hormonal parameters measured at baseline and after 1 month of placebo or empagliflozin.

Placebo (n = 13) Empagliflozin 10 mg (n = 26) Placebo vs. Empa



Blood Baseline 1 month Delta P-value Baseline 1 month Delta P-value P-value
Fasting plasma glucose (mmol/l) 4.81 ± 0.40 4.84 ± 0.34 + 0.02 ± 0.24 0.4 4.82 ± 0.37 4.72 ± 0.35 −0.1 ± 0.38 0.9 0.2
Insulin (mmol/l) 6.87 ± 3.04 6.90 ± 3.32 + 0.02 ± 2.46 0.9 6.79 ± 5.24 7.78 ± 5.10 +0.99 ± 4.42 0.3 0.5
HOMA-IR 1.5 ± 0.6 1.5 ± 0.7 + 0.0 ± 0.6 0.9 1.5 ± 1.2 1.7 ± 1.1 +0.2 ± 1.0 0.4 0.6
Ht,% 42.3 ± 3.4 42.0 ± 3.0 −0.3 ± 1.2 0.4 41.7 ± 3.2 42.3 ± 3.3 +0.6 ± 1.9 0.06 0.06
Hb, g/l 145 ± 12.3 145 ± 11.0 −0.2 ± 3.7 0.8 143 ± 11.4 146 ± 12.6 +2.5 ± 5.4 0.02 0.06
Sodium (mmol/l) 139 ± 1.3 139 ± 1.6 +0.2 ± 1.5 0.3 139 ± 1.7 139 ± 1.6 −0.3 ± 1.8 0.8 0.4
Potassium (mmol/l) 3.9 ± 0.3 4.0 ± 0.4 +0.2 ± 0.4 0.09 4.0 ± 0.2 4.0 ± 0.3 +0.0 ± 0.3 0.4 0.2
Creatinine (umol/l) 74.7 ± 11.3 74.3 ± 11.6 −0.4 ± 8.6 0.4 76.6 ± 11.4 76.3 ± 12.5 −0.3 ± 6.9 0.4 0.5
Urea (mmol/l) 4.3 ± 0.9 4.0 ± 0.9 −0.3 ± 0.9 0.2 4.0 ± 0.9 4.1 ± 0.8 +0.1 ± 0.7 0.4 0.05
Urate (umol/l) 274 ± 73.2 286 ± 91.1 +11.3 ± 35.5 0.2 303 ± 69.4 217 ± 52.5 −85.5 ± 35.6 <0.0001 <0.0001
Bicarbonate (mmol/l) 24.4 ± 1.9 25.2 ± 1.7 +0.7 ± 1.0 0.02 24.6 ± 2.5 24.5 ± 1.9 −0.1 ± 1.8 0.6 0.1
Plasma osmolality (mOsm/l) 300 ± 11.2 298 ± 4.5 −2.8 ± 10.4 0.4 300 ± 6.1 299 ± 9.1 −0.4 ± 8.4 0.9 0.4
Metanephrine (nmol/l) 0.15 ± 0.05 0.16 ± 0.06 + 0.004 ± 0.02 0.5 0.16 ± 0.07 0.16 ± 0.06 −0.006 ± 0.03 0.3 0.3
Normetanephrine (nmol/l) 0.21 ± 0.09 0.20 ± 0.09 −0.007 ± 0.05 0.6 0.20 ± 0.07 0.19 ± 0.06 −0.007 ± 0.05 0.5 0.9
PRA (ng/ml/h) 0.48 ± 0.24 0.43 ± 0.25 −0.05 ± 0.22 0.5 0.63 ± 0.44 0.81 ± 0.44 +0.18 ± 0.41 0.02 0.04
Aldosterone, pmol/l 42.7 ± 25.7 55.5 ± 27.2 +12.8 ± 27.4 0.06 66.3 ± 55.8 103 ± 83.4 +36.9 ± 61.3 0.002 0.09
Copeptin, pmol/l 5.3 ± 3.5 4.5 ± 1.9 −0.8 ± 2.5 0.3 5.7 ± 4.9 6.5 ± 4.1 +0.8 ± 3.7 0.3 0.2

HOMA-IR, Homeostatic Model Assessment for Insulin Resistance; HT, hematocrit, HB, hemoglobin; and PRA, plasma renin activity.